Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzo Biochem, Inc. (Enzo Biochem), a in vitro diagnostics company, announced that its Enzo Clinical Labs subsidiary, has appointed Kevin Krenitsky, as president. Krenitsky is a respected 12-year veteran of the life sciences industry, bringing a wealth of experience in building and managing global diagnostic operations. Prior to joining Enzo Clinical Labs, Krenitsky was chief executive officer (CEO) of Bioserve Biotechnologies Ltd. Prior to Bioserve, he was CEO of Parkway Clinical Laboratories.
Subscribe to our email newsletter
He previously served as senior vice president and division head at SeraCare Life Sciences’ Genomics Collaborative Division (GCI), where he managed all worldwide diagnostic and pharmaceutical R&D collaborations. Before GCI was acquired by Seracare Life Sciences, Krenitsky acted as the company’s medical director, responsible for spearheading the development of GCI’s global network of five hundred-plus clinical sites on four continents. During his tenure at GCI, Krenitsky was instrumental in developing several hundred agreements with dozens of major pharmaceutical, biotechnology, and diagnostic companies worldwide.
“Kevin’s impressive credentials in the clinical service, molecular diagnostics, and pre-clinical and clinical pharma, should serve us well as we continue to develop Enzo Clinical Labs into a molecular and esoteric center of excellence,” said Barry Weiner, president of Enzo Biochem “Kevin’s extensive operational experience along with his success in the launching of new service offerings will be instrumental in growing Enzo Clinical Labs.”